# FDA Approves LENZ Therapeutics' LNZ100 Ophthalmic Drug

> fda · REPORTED · 2025-07-31

LENZ Therapeutics announced on July 31, 2025 that the FDA approved LNZ100 in the United States, representing a major regulatory milestone for the company's lead ophthalmic product. The approval was announced via an SEC Form 8-K filing.

About LENZ Therapeutics: LENZ Therapeutics is a clinical-stage ophthalmic biopharmaceutical company focused on developing innovative eye drop therapies for vision conditions, targeting patients and eye care providers seeking non-surgical treatment alternatives.

- Company: LENZ Therapeutics
- Sector: therapeutics
- Primary source: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000059/lenz-20250731.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.